High blood pressure, medications increase diabetes risk

March 29, 2000

People with high blood pressure are two and a half times more likely to develop Type 2, or non-insulin-dependent, diabetes as those with normal blood pressure, according to a study led by researchers at Johns Hopkins and published in the March 30 issue of The New England Journal of Medicine.

The study also found the risk of diabetes to be 28 percent greater among patients who took beta blockers medications to reduce heart rate and the heart's output of blood than those who took no medication. Contrary to previous studies, however, the risk of diabetes among hypertensive patients taking thiazide diuretics was found to be lower than that of people not taking them.

"We're not suggesting that doctors stop prescribing beta blockers, as they have proven benefits in lowering the risk of cardiac events," says Frederick L. Brancati, M.D., M.H.S., associate professor of medicine and epidemiology at Hopkins. "But physicians need to weigh the benefits against the diabetes risk and monitor patients carefully.

"Physicians also should not be discouraged from prescribing thiazide diuretics, as our study did not find a causal link to diabetes. These are good medications to prevent heart disease and stroke."

As part of an ongoing study called Atherosclerosis Risk in Communities (ARIC), researchers analyzed nationwide data on 12,550 adults ages 45 to 64 who either had heart disease or were at risk for developing it. None had diabetes at the outset.

Patients underwent an extensive health evaluation at the study's start. Incidence of diabetes was assessed among the group after three years and again after six years.

During six years of follow-up, there were 1,146 new cases of diabetes. Of these, 569 occurred in patients with high blood pressure and 577 in people with normal blood pressure. Among the 3,804 adults who had high blood pressure at the study's start, those taking beta blockers were 28 percent more likely to develop diabetes than their counterparts not taking medication.

Among patients taking high blood pressure medications, those taking diuretics, angiotensin-converting-enzyme (ACE) inhibitors or calcium-channel antagonists were not at increased risk of diabetes. ACE inhibitors interfere with the body's production of angiotensin, a chemical that causes the arteries to constrict. Calcium channel blockers reduce heart rate and relax blood vessels.

The study was supported by the National Institutes of Health and the American Heart Association. Other authors were Todd W. Gress, M.D., M.P.H., and F. Javier Nieto, M.D., Ph.D., of Hopkins; Eyal Shahar, M.D., M.P.H., of the University of Minnesota; and Marion R. Wofford, M.D., M.P.H., of the University of Mississippi Medical Center.
-end-
Related Links:

Johns Hopkins' Welch Center for Prevention, Epidemiology and Clinical Research: http://www.med.jhu.edu/welchcenter/

National Institutes of Health: http://www.nih.gov

American Heart Association: http://www.americanheart.org

American Diabetes Association: http://www.diabetes.org

Media Contact: Karen Infeld 410-955-1534 Email:kinfeld@jhmi.edu

Johns Hopkins Medicine

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.